2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-180685
    N-Acetyldemethylphosphinothricin tripeptide 845880-13-9
    N-Acetyldemethylphosphinothricin tripeptide, a peptide antibiotic, is a compound with herbicidal activity. N-Acetyldemethylphosphinothricin tripeptide consists of the unusual amino acid phosphinothricin (PT) and two alanine residues. N-Acetyldemethylphosphinothricin tripeptide penetrates bacterial cells as a prodrug via peptide uptake systems with subsequent release of PT.
    N-Acetyldemethylphosphinothricin tripeptide
  • HY-180734
    Beta-alanyl-L-lysine 22467-93-2
    Beta-alanyl-L-lysine, a L-lysine dipeptide, is an endogenous metabolite found in tibetan sheep. Beta-alanyl-L-lysine (compound 2) shows antistaphylococcal and antifibrinolytic activities.
    Beta-alanyl-L-lysine
  • HY-180785
    G243-1720 932311-85-8
    G243-1720 is a potent, orally active, broad-spectrum anti-orthopoxvirus agent that functions by targeting the OPG57 (F13) protein and inducing its dimerization. G243-1720 effectively inhibits the replication of various poxviruses, but has no inhibitory effect on non-poxviruses. G243-1720 prevents the formation of extracellular membrane virus particles and the spread between cells. G243-1720 significantly reduces the viral load of monkeypox virus (MPXV) in the lungs of mice
    G243-1720
  • HY-180810
    T504 98%
    T504 is an oxazolidinone antibiotic. T504 exhibits significant growth inhibitory effects on Mycobacterium tuberculosis H37Rv, Mycobacterium bovis BCG, and Mycobacterium abscessus, and the MIC value for the reference strain Mycobacterium tuberculosis H37Rv is 0.5-1.0 μg/mL. T504 effectively inhibits the growth of Mycobacterium tuberculosis within macrophages and does not show obvious cytotoxicity. T504 can be used in the research of mycobacterial infections.
    T504
  • HY-180883
    ZW-2038
    ZW-2038 is a potent and selective antiviral compound against vaccinia virus (VACV), monkeypox virus (MPXV), and cowpox virus (CPXV). ZW-2038 suppresses VACV DNA replication and downstream post-replicative gene expression, albeit without inhibiting MPXV resolvase (Mpr). ZW-2038 demonstrates potent antiviral activity in complex human and animal tissue models. ZW-2038 can be used for orthopoxviruses infection research.
    ZW-2038
  • HY-180887
    A-692345 877298-56-1
    A-692345 is a naphthyridone antibiotic. A-692345 exhibits antibacterial activity against S. aureus with a MIC of 8 µg/mL. A-692345 can be used for antimicrobial research.
    A-692345
  • HY-180953
    Fmoc-NH-C2-diphosphate-dexamethasone 1815577-55-9
    Fmoc-NH-C2-diphosphate-dexamethasone (Compound 17) is a derivative of Dexamethasone (HY-14648) and can be used as a drug intermediate for the synthesis of the Raltitrexed (HY-10821)-Dexamethasone conjugate.
    Fmoc-NH-C2-diphosphate-dexamethasone
  • HY-181008
    Antitubercular agent-56
    Antitubercular agent-56, a Questiomycin A (HY-N8439) derivative, is a potent and orally active antitubercular agent. Antitubercular agent-56 disrupts mycobacterial envelope integrity by inhibiting FabD (Kd = 9.39 μM; IC50 = 49.60 μM). Antitubercular agent-56 exhibits good intracellular antimycobacterial activity against Mycobacterium tuberculosis (MTB) and drug-resistant MTB both in vitro and in vivo. Antitubercular agent-56 can be used for research on tuberculosis (TB).
    Antitubercular agent-56
  • HY-181033
    (M)-AVI-4773 3111610-68-2
    (M)-AVI-4773 is an orally active, blood-brain barrier permeable coronaviruses MPro inhibitor with an IC50 of 2.5 nM aginst SARS-CoV-2 MPro. (M)-AVI-4773 produces a rapid onset antiviral effect in mouse models of MERS-CoV and SARS-CoV-2 infection.
    (M)-AVI-4773
  • HY-181066
    ACE2-SP PPI-IN-1
    ACE2-SP PPI-IN-1 is an inhibitor of the interaction between the SARS-CoV-2 spike protein and ACE2, with an IC50 of 2162.77 nM. ACE2-SP PPI-IN-1 exhibits low cytotoxicity in human fibroblasts. ACE2-SP PPI-IN-1 binds to the interface region between the spike protein RBD and ACE2, reducing the flexibility of the critical receptor-binding loop and maintaining the structural compactness of the spike protein. ACE2-SP PPI-IN-1 can be used for research related to SARS-CoV-2.
    ACE2-SP PPI-IN-1
  • HY-181108
    GSK190937 2651234-01-2
    GSK190937 is a type II platelet-derived growth factor receptor alpha (PDGFRA) human kinase inhibitor with antimalarial activity. GSK190937 can inhibit the formation of hemozoin in the malaria parasite, resulting in the accumulation of free hemoglobin within the malaria parasite. GSK190937 shows IC50 values of 0.22, 0.59 and 0.25 μM against P. falciparum NF54, K1 and Dd2 parasite. GSK190937 shows an IC50 of 25 μM for CHO cells. GSK190937 can be used for research of malaria.
    GSK190937
  • HY-181144
    COX-2-IN-65 1408337-43-8
    COX-2-IN-65 is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 10.24 μM. COX-2-IN-65 inhibits Staphylococcus aureus and Escherichia coli growth. COX-2-IN-65 scavenges reactive oxygen species (ROS). COX-2-IN-65 can be used for the researches of bacterial infections and inflammation.
    COX-2-IN-65
  • HY-181146
    MK-7762 2706576-88-5 98%
    MK-7762 is an orally active xazolidinone compound with antitubercular activity. MK-7762 inhibits MAO-B and mammalian mitochondrial protein synthesis. MK-7762 reduces lung bacterial burden in BALB/c mouse models of acute and chronic tuberculosis infection, penetrates caseous necrotic lung lesions in C3HeB/FeJ mice, and maintains concentrations above unbound MIC in lesion compartments. MK-7762 can be used for the research of tuberculosis.
    MK-7762
  • HY-181164
    PROTAC BRD4 Degrader-43 98%
    PROTAC BRD4 Degrader-43 is a BRD4 PROTAC degrader. PROTAC BRD4 Degrader-43 recruits the DCAF1-DDB1-Cul4A E3 ligase complex via a Vpr-derived peptide moiety to induce BRD4 ubiquitination and degradation through the ubiquitin-proteasome system. PROTAC BRD4 Degrader-43 exhibits potent HIV latency-reversing activity. PROTAC BRD4 Degrader-43 can be used for the research of HIV-1 latent infection. (Pink: BRD4 ligand (HY-13030); Blue: Cul4A-DDB1-DCAF1 ligand (HY-P11640); Black: conjugate of PEG linker + cell-penetrating peptide (HY-P2483))
    PROTAC BRD4 Degrader-43
  • HY-181231
    PROTAC CDK9 degrader-12 3052648-82-2 98%
    PROTAC CDK9 degrader-12 is a selective CDK9 PROTAC degrader with a DC50 of 23 nM. PROTAC CDK9 degrader-12 induces proteasome-dependent degradation of CDK9, blocks CDK9-mediated HIV-1 transcriptional elongation, and reduces HIV-1 RNA synthesis. PROTAC CDK9 degrader-12 is applicable to research related to HIV-1 infection.
    PROTAC CDK9 degrader-12
  • HY-181263
    Jun13698 98%
    Jun13698 is a SARS-CoV-2 main protease (Mpro) inhibitor with Ki values of 65.6 nM, 510.0 nM, and 117.5 nM against the wild-type, E166V, and E166A mutants, respectively. Jun13698 forms stable complexes with wild-type and mutant Mpro to mediate enzyme inhibition. Jun13698 exhibits antiviral activity against SARS-CoV-2 variants carrying the E166V/A mutation. Jun13698 is applicable to COVID-19-related research.
    Jun13698
  • HY-181264
    Antifungal agent 153 98%
    Antifungal agent 153, a derivative of Blasticidin S (HY-103401A), is an antibacterial agent. Antifungal agent 153 retains the antibacterial activity of Blasticidin S, exhibits potent inhibitory effects against multidrug-resistant Gram-positive bacteria, and significantly reduces mammalian cytotoxicity. Antifungal agent 153 can be used in studies related to bacterial infections.
    Antifungal agent 153
  • HY-181275
    CDK9 ligand 4 2609749-29-1
    CDK9 ligand 4 is a CDK9 ligand. As a ligand for target protein for PROTAC (Ligands for Target Protein for PROTAC), CDK9 ligand 4 serves for the development and design of PROTAC CDK9 degraders, such as PROTAC CDK9 degrader-12 (HY-181231). CDK9 ligand 4 is applicable to the research of HIV-1 infection.
    CDK9 ligand 4
  • HY-181282
    MSU-44147 3105177-29-2 98%
    MSU-44147 is an inhibitor and antimicrobial agent targeting MmpL3 in Mycobacterium abscessus, with low eukaryotic cytotoxicity, a narrow antimicrobial spectrum that is specific only to mycobacteria, and low drug resistance frequency. MSU-44147 reduces trehalose dimycolate levels by inhibiting MmpL3 function, disrupts biofilm formation and reduces the viability of related bacteria, while exerting bactericidal effects on intracellular Mycobacterium abscessus. MSU-44147 exhibits additive or synergistic effects with antibiotics and can be used in research on multidrug-resistant isolates and infections of Mycobacterium abscessus.
    MSU-44147
  • HY-181283
    MSU-43557 2919699-59-3 98%
    MSU-43557 is a Mycobacterium abscessus MmpL3 (MAB_4508) inhibitor and bactericidal agent. MSU-43557 inhibits MmpL3 function, disrupts trehalose monomycolate synthesis, and reduces biofilm-associated Mycobacterium abscessus viability. MSU-43557 exerts bactericidal activity against intracellular Mycobacterium abscessus. MSU-43557 shows low eukaryotic cytotoxicity and low Mycobacterium abscessus resistance frequency. MSU-43557 can be used for the research of mycobacterium abscessus infection.
    MSU-43557
Cat. No. Product Name / Synonyms Application Reactivity